CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.270
+0.090 (4.13%)
At close: Jan 23, 2025, 4:00 PM
2.241
-0.029 (-1.26%)
After-hours: Jan 23, 2025, 6:46 PM EST
CervoMed Employees
CervoMed had 8 employees as of December 31, 2023. The number of employees increased by 4 or 100.00% compared to the previous year.
Employees
8
Change (1Y)
4
Growth (1Y)
100.00%
Revenue / Employee
$1,258,319
Profits / Employee
-$1,493,397
Market Cap
18.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
CRVO News
- 6 weeks ago - CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Benzinga
- 6 weeks ago - CervoMed's stock craters 77% after failed trial of treatment for rare brain disease - Market Watch
- 6 weeks ago - CervoMed's dementia drug fails to meet mid-stage trial goals - Reuters
- 6 weeks ago - CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia - GlobeNewsWire
- 2 months ago - CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup - GlobeNewsWire